negative regulator of P-body associationGenealiases: LINC01420 · NoBody
Q-omics provides the consensus-scored NBDY profile across patient tissues and cancer cell-line models. NBDY expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, NBDY is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, NBDY RNA expression shows 19,049 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, COAD, and ACC as cancer lineages where NBDY shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NBDY — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NBDY survival associations across molecular data types. NBDY RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NBDY RNA expression–survival associations across cancer types. High NBDY expression shows unfavorable associations in LUAD, KIRP, HNSC, STAD and LGG, but favorable associations in LUSC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for NBDY RNA expression.
This table summarizes NBDY tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NBDY. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NBDY shows higher tumor expression in COAD, HNSC, BRCA, BLCA, LIHC and KIRC. The COAD box plot shows higher NBDY RNA expression in tumor versus normal tissue (log2 FC = +0.660, t-test p < 0.001).
This table shows molecular features associated with NBDY in patient tissues and cancer cell lines. In patient samples, NBDY shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NBDY RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LUNG_SCLC.
